11? Hydroxysterold dehydrogenases (11?-HSDs )catalyse the interconversion of active glucocorticoids(cortisol,corticosterone )and their inert 11?-keto derivatives(cortisone,11-dehydrocorticosterone)They play an important role in regulating the local glucocorticoids activities.Glucoeorticoids can induce insulin resistance.The alteration of 11?-HSD activities in tissues such as liver ,adipose tissue, is closely relevant to some common disorders,including obesity and type 2diabetes mellitus.

The growth factor receptor -bound protein-2 (Grb2) is an adapter protein in cells. Over expression of Grb2 is found in many kinds of tumor and plays an important role in tumor proliferation and progression. So it may be a molecular target for anti-tumor therapy.

Objective To explore the relationship between transitional care model and diabetic patients. Methods 112 patients with type 2 diabetes mellitus were divided into observation group and control group according to random number table. Control group used the doctor as the center patient management mode. The observation group used thepatient-centeredpatient management, application of home nursing service. Results Glycosylated hemoglobin (HbA1c), triglyceride (TG), high-density lipoprotein (HGL), 2 h postprandial blood glucose (2hPBG), fasting blood glucose (FBG), body mass index (BMI) of observation group before treatment respectively were (11.2±2.4)%, (3.7±1.3) mmol/L, (0.5±0.2) mmol/L, (13.6±2.4) mmol/L, (11.8±2.9) mmol/L, (25.9±4.9) kg/m2. Patients discharged from hospital after care for 3 months respectively were (6.8±0.9)%, (1.0±0.3) mmol/L, (2.5±0.4) mmol/L, (8.9±1.5) mmol/L, (6.8 ± 2.0) mmol/L, (20.8 ± 5.8) kg/m2. There was statistically significant difference (t=3.5-6.6,P<0.05). Control group before treatment respectively were (11.9 ± 3.6) %, (3.8 ± 1.5) mmol/L, (0.6 ± 0.3) mmol/L, (13.9 ± 2.9) mmol/L, (11.6 ± 3.2) mmol/L, (25.9 ± 6.8) kg/m2,while patients discharged from hospital for 3 months respectively were (10.9±3.4)%, (3.3±0.7) mmol/L, (0.7±0.2) mmol/L, (12.8±4.2) mmol/L, (10.6± 2.6) mmol/L, (25.1 ± 6.6) kg/m2, there was no statistically significant difference (t=0.05-1.36,P>0.05). Patients discharged from hospital after 3 months, perception, diet, medication, exercise adherence score of observation group was (34.98 ± 5.67), (41.98 ± 5.00), (40.29 ± 5.60), (40.45 ± 7.21) points, which were obviously higher than (21.18±4.75) , (28.46±4.26), (21.88±4.58), (20.98±2.69) points of control group, the difference was statistically significant (t=13.96-19.03,P<0.01). Conclusions Using home nursing service mode in type 2 diabetes care is helping to improve blood sugar levels and improve patient compliance after discharge, fully improve the patients′prognosis.

Child ; Congresses as Topic ; Humans ; Nephrology ; Pediatrics

Child ; China ; Chronic Disease ; Congresses as Topic ; Humans ; Kidney Diseases ; prevention & control ; Kidney Failure, Chronic ; prevention & control ; Renal Insufficiency, Chronic ; prevention & control

Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Hypertension, Renal ; Infant ; Male ; Retrospective Studies

Autoantibodies ; Child ; Complement Factor H ; immunology ; Female ; Hemolytic-Uremic Syndrome ; immunology ; Humans

Objective: To study in vivo pharmacokinetic characteristic of supersaturable self microemulsion drug delivery system (S-SMEDDS) of silybin in rats. Methods: According to the random design, 12 male rats were divided into one control group and one experimental group by six each. SMEDDS of silybin was given to the control group and S-SMEDDS of silybin to the experimental group by both ig administration at dosage of 533 mg/kg, respectively. Blood sampling was conducted by means of an automated blood sampling device (Accusampler) at different time points. After ig administration of S-SMEDDS of silybin to rats, the silybin concentrations in plasma were determined by HPLC and the pharmacokinetic parameters were calculated by non-compartment model of statistical moment analysis. Results: The main pharmacokinetic parameters of the control and experimental groups were as follows: tmax is (1.00 ± 0.40) and (1.50 ± 0.84) h, Cmax is (5.68 ± 0.52) and (16.10 ± 4.06) μg/mL, AUC0→1 is (27.30 ± 3.29) and (82.64 ± 12.36) μg·h·mL-1, respectively. Conclusion: This assessment demonstrates that the oral absorption bioavailability could be substantially improved via the approach: by S-SMEDDS of silybin.

AIM: To investigate the association between cycloxygenase-2 (COX-2) expression and VEGF intervention as well as the inhibitory effect of Meloxicam on the cultured human pterygium fibroblasts (HPF).METHODS: Expression of COX-2 was measured by immunohistochemistry in the cultured HPF from twenty excised pterygium cases. Expression of COX-2 in HPF was measured by Western blot following the treatment of vascular endothelial growth factor (VEGF) at the different concentrations. In addition, the effect of Meloxicam on proliferation of HPF was studied by adding the different concentrations into the cultured HPF plates by Mono-nuclear cell direct cytotoxicity (MTT) reduction assay.RESULTS: COX-2 expression was present in the cultured HPF. The level of the expression increased following VEGF treatment. The proliferation of the cultured HPF decreased following addition of the different concentrations of Meloxicam (from 75μ mol/L to 300μ mol/L) and the magnitude of the inhibition was dose-time dependent.CONCLUSION: COX-2 levels in the cultured HPF werepositively associated with VEGF stimulation and Meloxicam was inhibitory to HPF proliferation.

Objective To explore the clinical significance of the serum Epstein-Barr virus determined nuclear antigen 1 (EBNA1)/latent membrane protein 1 (LMP1) in patients with extranodal NK/T-cell lymphoma,nasal type (ENKL).Methods The serum EBNA1 and LMP1 were detected by realtime PCR in 36 ENKL patients hospitalized in Beijing Tongren Hospital from August 2010 to August 2013.Twenty healthy volunteers were recruited as controls.Results The median serum EBNA1 was 1.9 × 104 (ranged from 0 to 11.0 × 104) copies/μl in ENKL patients and 8.0 (ranged from 0 to 43.8) copies/μl in healthy volunteers.The median serum LMP1 was 3.9 × 103 (ranged from 118.3 to 24.0 × 103) copies/μl in ENKL patients and 3.3 (ranged from 0 to 33.3) copies/μl in healthy volunteers.Both EBNA1 and LMP1 were higher in ENKL patients than healthy volunteers (all P ＜ 0.01).The median EBNA1 and LMP1 in ENKL patients posttreatment were 1.0 × 103 (ranged from 0 to 2.0 × 103) copies/μl and 300.8(ranged from 0 to 825.7) copies/μl respectively,which were both significantly decreased than pretreatment (all P ＜ 0.05).The EBNA1 and LMP1 were decreased in effective treatment group versus ineffective treatment group (P ＜0.05).The serum EBNA1 and LMP1 were positively correlated with lactic dehydrogenase (LDH) level (r =0.364,0.546 ; P =0.040,0.012).Conclusions (1) The measurement of EBNA1/LMP1 may be useful in evaluating the therapeutic effect.(2)The serum EBNA1/LMP1 may reflect the tumor load in ENKL patients.